Anlage 1 EMBASE Recherche vom 16.09.2010 Suchschritt : ((FT=interleukin-2 AND FT=hiv ) AND FT=randomized ) AND (LA=ENGLISH OR LA=GERMAN) AND (pps=AIDS OR pps=Mensch) » Volltext-Angebot » 4/1 von 127 DIMDI: EMBASE (EM00) © 2010 Elsevier B.V. ND: EM2010463395 Autoren: Bosch RJ; Pollard RB; Landay A; Aga E; Fox L; Mitsuyasu R Titel: Continuing or adding IL-2 in patients treated with antiretroviral therapy (ACTG Protocol A5051, a rollover trial of ACTG Protocol A328) Source: AIDS Research and Therapy; VOL: 7 /20100805/ http://www.aidsrestherapy.com/content/7/1/30 NCT: ClinicalTrials.gov-NCT00000923 ANR: 30 DOI: 10.1186/1742-6405-7-30 PU: BioMed Central Ltd. SU: EMBASE Sprache: English AL: English CY: United Kingdom ISSN: 1742-6405 Institution: Bosch RJ, Harvard School of Public Health, Boston MA, United States, [email protected] COU: United States DT: Journal Article RN: 0006 Keywords AB: Background: Effective antiretroviral therapy reduces HIV-1 RNA levels, improves CD4 T-cell counts, and lowers the risk of opportunistic infections and malignancies. Interleukin-2 (IL-2) has been shown to increase CD4 T-cell numbers mainly by expanding CD4 cells and by prolonging their half-lives. HIV-infected patients previously enrolled into A328 had been randomized to antiretroviral therapy (ART) alone or ART followed by IL-2. In A5051, 53 patients from A328 who had previously received IL-2 were allowed to continue IL-2 for an additional 80 weeks; 27 patients who had received ART alone received IL-2 for 80 weeks.Results: The patients previously receiving IL-2 continued to have elevated CD4 levels with extended use of IL-2. The prior ART-alone recipients had increases in CD4 levels to comparable levels as the prior IL-2 recipients (median 804 versus 847 cells/mm<sup>3 </sup>at week 72; 60% versus 9% had >50% increase in A5051 to week 72, p < 0.001). Those who had previously received IL-2 required fewer IL-2 cycles to maintain their CD4 T-cell counts compared to those newly initiating IL-2. The treatments were well tolerated with no significant differences in toxicity or discontinuations between those newly versus previously receiving IL-2. There were few clinical events observed.Conclusions: Although sustained CD4 T-cell count increases were seen with IL-2 administration as in other studies, the absence of clinical benefit in two recent randomized trials has demonstrated no apparent role for IL-2 as a therapy in HIV disease.Trial Registration: A5051 ClinicalTrials.gov Identifier: NCT00000923. © 2010 Bosch et al; licensee BioMed Central Ltd. PU: BioMed Central Ltd. 34 - 42 Cleveland Street, London, W1T 4LB, United Kingdom CNOTE: Copyright 2010 Elsevier B.V., All rights reserved. » Volltext-Angebot » 4/2 von 127 DIMDI: EMBASE (EM00) © 2010 Elsevier B.V. ND: EM2010299950 Autoren: Blish CA; Sangaré L; Herrin BR; Richardson BA; John-Stewart G; Walson JL Titel: Changes in plasma cytokines after treatment of Ascaris lumbrkoides infection in individuals with HIV-1 infection Source: Journal of Infectious Diseases; VOL: 201 (12); p. 1816-1821 /20100615/ NCT: ClinicalTrials.gov-NCT00130910 DOI: 10.1086/652784 PU: University of Chicago Press SU: EMBASE Sprache: English AL: English CY: United States ISSN: 0022-1899 CO: JIDIA Institution: Walson JL, Box 359909, 325 Ninth Ave, Seattle, WA 98104, United States, [email protected] COU: United States DT: Journal Article JSC: E.5 ... Clinical Microbiology; B.2 ... Public Health RN: 0015 AB: Albendazole treatment of individuals with human immunodeficiency virus type 1 (HIV-1) and Ascaris lumbricoides coinfection has led to significantly improved CD<sup>4+</sup> cell counts and a trend for lower plasma HIV-1 RNA levels in a previous randomized placebo-controlled trial. To define mechanisms by which deworming contributed to changes in markers of HIV-1 disease progression, plasma cytokine levels were evaluated. Albendazole treatment, compared with placebo, was associated with significantly decreased plasma interleukin (IL) 10 levels (P = .04) but was not associated with significant changes in levels of IL-1 beta , IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-12p70, IL-13, interferon gamma , tumor necrosis factor a, or thymic stromal lymphopoietin. Treatment of A. lumbricoides co-infection may delay HIV-1 disease progression by reducing helminth-in-duced, IL- 10-mediated immunosuppression. © 2010 by the Infectious Diseases Society of America. All rights reserved. PU: University of Chicago Press 1427 E. 60th Street, Chicago, IL 60637-2954, United States CNOTE: Copyright 2010 Elsevier B.V., All rights reserved. » Volltext-Angebot » 4/3 von 127 DIMDI: EMBASE (EM00) © 2010 Elsevier B.V. ND: EM2010228334 Autoren: Markowitz M; Vaida F; Bradley Hare C; Boden D; Mohri H; Hecht FM; Kalayjian RC; Conrad A; Mildvan D; Aberg J; Hogan C; Michael Kilby J; Balfour HH Jr.; Schafer K; Richman D; Little S Titel: The virologie and immunologic effects of cyclosporine as an adjunct to antiretroviral therapy in patients treated during acute and early HIV-1 infection Source: Journal of Infectious Diseases; VOL: 201 (9); p. 1298-1302 /20100501/ DOI: 10.1086/651664 PU: University of Chicago Press SU: EMBASE Sprache: English AL: English CY: United States ISSN: 0022-1899 CO: JIDIA Institution: Markowitz M, Dr., Aaron Diamond AIDS Research Center, 455 First Ave, New York, NY 10016, United States, [email protected] COU: United States DT: Journal Article JSC: E.5 ... Clinical Microbiology; B.2 ... Public Health RN: 0015 Keywords AB: Acute human immunodeficiency virus type 1 (HIV-1) infection is characterized by high levels of immune activation. Immunomodulation with cyclosporine combined with antiretroviral therapy (ART) in the setting of acute and early HIV-1 infection has been reported to result in enhanced immune reconstitution. Fifty-four individuals with acute and early infection were randomized to receive ART with 4 weeks of cyclosporine versus ART alone. In 48 subjects who completed the study, there were no significant differences between treatment arms in levels of proviral DNA or CD4+ T cell counts. Adjunctive therapy with cyclosporine in this setting does not provide apparent virologie or immunologic benefit. © 2010 by the Infectious Diseases Society of America. All rights reserved. PU: University of Chicago Press 1427 E. 60th Street, Chicago, IL 60637-2954, United States CNOTE: Copyright 2010 Elsevier B.V., All rights reserved. » Volltext-Angebot » 4/4 von 127 DIMDI: EMBASE (EM00) © 2010 Elsevier B.V. ND: EM2010179610 Autoren: Tavel JA; Babiker A; Carey C; Fisher M; Fox L; Gey D; Lopardo GD; Lopez JC; Markowitz N; Munroe D; Paton N; Ruxrungtham K; Standridge B; Wentworth D; Wyman N; Aagaard B; Borup L; Grarup J; Jansson P-O; Jensen K; Lundgren J; Mollerup D; Reilev S; Braimah N; Darbyshire J; Horton J; King E; Smith N; Van Hooff F; Cooper DA; Courtney-Rodgers D; Emery S; Finley E; Gordin F; Sánchez A; Thomas D; Bebchuk J; Bollenbeck P; Denning E; DuChene AG; Fosdick L; Harrison M; Krum E; Larson G; Neaton JD; Nelson R; Quan K; Quan S-FL; Schultz T; Thompson G; Collins S; Haerry DH; Meulbroek M; Peavy D; Rappoport C; Schwarze S; Valdez M; Watson J; Belloso WH; Davey R; Duprez D; Gatell JM; Hoy J; Lifson A; Pederson C; Perez G; Price R; Prineas R; Rhame F; Sampson JH; Worley J; Modlin JF; Beral V; Chaisson RE; Fleming TR; Hill C; Kim K; Murray BE; Pick B; Seligmann M; Weller I; Luzar MA; Martinez A; Costas V; Eckstrand J; Brown S; Lupo SH; Losso MH; Anderson J; Chuah J; Kelly M; Orth D; Wolff MJ; Rusconi S; Tambussi G; Horban A; Antunes F; Mansinho K; Da Conceicao Vera JAV; Himmich H; Chetchotisakd P; Kantipong P; Orkin C; Portsmouth S; Winston A; Wiselka MJ; Anstead GM; Arduino RC; Goetz MB; Hennessey K; El-Sadr W; Labriola AM; Nixon DE; Rodriguez-Barradas MC Titel: Effects of intermittent IL-2 alone or with peri-cycle antiretroviral therapy in early HIV infection: The STALWART study Source: PLoS ONE; VOL: 5 (2) /20100223/ http://www.plosone.org/article/fetchObjectAttachment.action?uri=info%3Adoi%2F10.1371%2Fjournal.pone.0009334&representation=PDF NCT: ClinicalTrials.gov-NCT00110812 ANR: e9334 DOI: 10.1371/journal.pone.0009334 PU: Public Library of Science SU: EMBASE Sprache: English AL: English CY: United States EISSN: 1932-6203 Institution: Tavel JA, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States, [email protected] COU: United States DT: Journal Article RN: 0029 AB: Background: The Study of Aldesleukin with and without antiretroviral therapy (STALWART) evaluated whether intermittent interleukin-2 (IL-2) alone or with antiretroviral therapy (ART) around IL-2 cycles increased CD4<sup>+</sup> counts compared to no therapy. Methodology: Participants not on continuous ART with >=300 CD4<sup>+</sup> cells/mm³ were randomized to: no treatment; IL-2 for 5 consecutive days every 8 weeks for 3 cycles; or the same IL-2 regimen with 10 days of ART administered around each IL-2 cycle. CD4 <sup>+</sup> counts, HIV RNA, and HIV progression events were collected monthly. Principal Findings: A total of 267 participants were randomized. At week 32, the mean CD4<sup>+</sup> count was 134 cells greater in the IL-2 alone group (p<0.001), and 133 cells greater in the IL-2 plus ART group (p<0.001) compared to the no therapy group. Twelve participants in the IL-2 groups compared to 1 participant in the group assigned to no therapy experienced an opportunistic event or died (HR 5.84, CI: 0.59 to 43.57; p = 0.009). Conclusions: IL-2 alone or with peri-cycle HAART increases CD4<sup>+</sup> counts but was associated with a greater number of opportunistic events or deaths compared to no therapy.